modernretina.com

Webbplats analys modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Genereras på Mars 31 2026 15:12 PM

Gammal statistik? UPDATERA !

Ställningen är 57/100

SEO Innehåll

Titel

Modern Retina – Ophthalmology News, Events & Expert Insights

Längd : 60

Perfekt, din titel innehåller mellan 10 och 70 tecken.

Beskrivning

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Längd : 155

Bra, din metabeskrivning innehåller mellan 70 och 160 tecken.

Nyckelord

Mycket dåligt. Vi har inte lyckats hitta några meta-taggar på din sida. Använd denna meta-tag generator, gratis för att skapa nyckelord.

Og Meta Egenskaper

Bra, din sida drar nytta utav Og.

Egendom Innehåll
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Rubriker

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Bilder

Vi hittade 135 bilder på denna webbsida.

23 alt attribut är tomma eller saknas. Lägg till alternativ text så att sökmotorer enklare kan förstå innehållet i dina bilder.

Text/HTML Ratio

Ratio : 3%

Denna sidas förhållande mellan text till HTML-kod är lägre än 15 procent, vilket innebär att din webbplats troligen behöver mer textinnehåll.

Flash

Perfekt, inga Flash-innehåll har upptäckts på denna sida.

Iframe

Bra, vi upptäckte inga Iframes på den här sidan.

URL Rewrite

Bra. Dina adressfält ser bra ut!

Understreck i URLen

Perfekt! Inga understreck upptäcktes i din webbadress.

In-page länkar

Vi hittade totalt 89 länkar inklusive 0 länk(ar) till filer

Anchor Typ Juice
All News Interna Passing Juice
Blogs Interna Passing Juice
All Videos Interna Passing Juice
Case-Based Roundtable Series Interna Passing Juice
Eichenbaum Acorns Interna Passing Juice
Expert Interviews Interna Passing Juice
Eyeviews Interna Passing Juice
Insights Interna Passing Juice
Medical World News Externa Passing Juice
Podcasts Interna Passing Juice
Rapid Readouts Interna Passing Juice
The Retina TL;DR Interna Passing Juice
Viewpoints Interna Passing Juice
Conference Coverage Interna Passing Juice
Conference Listing Interna Passing Juice
Modern Retina Digital Edition Interna Passing Juice
Supplements And Featured Publications Interna Passing Juice
Between the Lines Interna Passing Juice
CME/CE Interna Passing Juice
EYLEA 8mg for nAMD and DME Treatment Interna Passing Juice
Sponsored Resources Interna Passing Juice
Partners Interna Passing Juice
Subscribe Interna Passing Juice
AMD Interna Passing Juice
Wet AMD Interna Passing Juice
Biosimilar Interna Passing Juice
Diabetic Macular Edema Interna Passing Juice
Diabetic Eye Awareness Interna Passing Juice
Diabetic Retinopathy Interna Passing Juice
Geographic Atrophy Interna Passing Juice
Imaging Interna Passing Juice
Inherited Retinal Diseases Interna Passing Juice
Ophthalmology Interna Passing Juice
RVO Interna Passing Juice
Retina Technology Interna Passing Juice
Retinal Surgery Interna Passing Juice
Uveitis Interna Passing Juice
Geographic Atrophy Interna Passing Juice
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Interna Passing Juice
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Interna Passing Juice
Treating MacTel: First identify patient candidates and appropriate eye selection Interna Passing Juice
A medical fellow finds some magic at the AAO Annual Meeting Interna Passing Juice
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Interna Passing Juice
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Interna Passing Juice
FLORetina 2025: Long-term follow-up in pediatric gene therapy Interna Passing Juice
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Interna Passing Juice
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Interna Passing Juice
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Interna Passing Juice
Martin David Harp Interna Passing Juice
Christina Y. Weng, MD, MBA, FASRS Interna Passing Juice
View All Interna Passing Juice
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Interna Passing Juice
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Interna Passing Juice
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Interna Passing Juice
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Interna Passing Juice
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Interna Passing Juice
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Interna Passing Juice
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Interna Passing Juice
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Interna Passing Juice
Integrating AI to manage DR in a primary care setting Interna Passing Juice
What to expect from virtual AAO 2020 Interna Passing Juice
View More Interna Passing Juice
Navigating geographic atrophy from biomarkers to bilateral therapy Interna Passing Juice
8 things to know about aflibercept 8 mg for retinal vascular disease Interna Passing Juice
Inside the mindset of an early adopter Interna Passing Juice
Challenges for young physicians treating patients with GA Interna Passing Juice
AAO highlight: Looking ahead to 2026 Interna Passing Juice
How AI is reshaping ophthalmology in 2025 and beyond Interna Passing Juice
Seeing the difference: Multimodal imaging for AMD and GA Interna Passing Juice
Ryan Livingston Interna Passing Juice
Lynda Charters Interna Passing Juice
Kevin Kunzmann Interna Passing Juice
Jeffry D. Gerson, OD, FAAO Interna Passing Juice
Theodore Leng, MD, MS Interna Passing Juice
Sheryl Stevenson Interna Passing Juice
Joshua Mali, MD Interna Passing Juice
Arshad M. Khanani, MD, MA, FASRS Interna Passing Juice
Modern Retina Staff Reports Interna Passing Juice
Jayanth Sridhar, MD Interna Passing Juice
Matt Hoffman Interna Passing Juice
Sheila Setork, OD Interna Passing Juice
About Interna Passing Juice
Advertise Interna Passing Juice
Editorial Interna Passing Juice
Contact Us Interna Passing Juice
Terms and Conditions Interna Passing Juice
Privacy Interna Passing Juice
Do Not Sell My Personal Information Externa Passing Juice
Home Interna Passing Juice

SEO Nyckelord

Nyckelord Moln

faao view management fasrs cope retinal video more cme track

Nyckelord Konsistens

Nyckelord Innehåll Titel Nyckelord Beskrivning Rubriker
more 64
view 52
video 44
track 35
faao 24

Användbarhet

Url

Domän : modernretina.com

Längd : 16

Favikon

Bra, din webbplats har en favicon.

Utskriftbart

Vi kunde inte hitta CSS för utskrifter.

Språk

Bra. Ditt angivna språk är en.

Dublin Core

Denna sida drar inte nytta utav Dublin Core.

Dokument

Doctype

HTML 5

Encoding

Perfekt. Din deklarerade teckenuppsättning är UTF-8.

W3C Validity

Errors : 0

Varningar : 0

E-post Sekretess

Varning! Minst en e-postadress har påträffats i klartext. Använd gratis antispam skydd för att dölja e-post från spammare.

Föråldrad HTML

Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.

Hastighets Tips

Utmärkt, din webbplats använder inga nästlade tabeller.
Synd, din webbplats använder sig utav inline stilar.
Bra, din webbplats har få CSS-filer.
Synd, din webbplats har för många JS filer (fler än 6 stycken).
Perfekt, din webbplats utnyttjar gzip.

Mobil

Mobiloptimering

Apple Ikon
Meta Viewport Tagg
Flash innehåll

Optimering

XML Sitemap

Bra, din webbplats har en XML sitemap.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Bra, din webbplats har en robots.txt fil.

Analytics

Bra, din webbplats har ett analysverktyg.

   Google Analytics

PageSpeed Insights

Enhet
Kategorier

Free SEO Testing Tool

Free SEO Testing Tool är en fri SEO verktyg som hjälper dig att analysera din webbplats